Pilot trial of bone‐targeted therapy with zoledronate, thalidomide, and interferon‐γ for metastatic renal cell carcinoma

The purpose of the study was to evaluate the efficacy and safety of a bone‐targeted regimen consisting of zoledronate, thalidomide, and interferon‐γ in patients with renal cell carcinoma and bone metastases.

[1]  F. Saad,et al.  Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Motzer,et al.  AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) , 2005 .

[3]  R. Bukowski,et al.  Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .

[4]  M. Atkins,et al.  Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma , 2004, Clinical Cancer Research.

[5]  G. Roodman.  Mechanisms of bone metastasis. , 2004, Discovery medicine.

[6]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Lipton,et al.  Zoledronic acid delays the onset of skeletal‐related events and progression of skeletal disease in patients with advanced renal cell carcinoma , 2003, Cancer.

[8]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[9]  P. Thall,et al.  A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma , 2002, Cancer.

[10]  L. Demers,et al.  Biochemical markers and skeletal metastases. , 2001, Clinical orthopaedics and related research.

[11]  K. Inoue,et al.  Diagnostic value of bone‐turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma , 2001, Cancer.

[12]  Hiroshi Takayanagi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.

[13]  P. Haslett,et al.  Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.

[14]  M. Gleave,et al.  Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma , 1999 .

[15]  D. Lacombe,et al.  Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion , 1999, British Journal of Cancer.

[16]  G. Hortobagyi,et al.  Markers of bone resorption in patients treated with pamidronate. , 1998, European journal of cancer.

[17]  P. Croucher,et al.  The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. , 1998, Cancer research.

[18]  P. Haslett,et al.  Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset , 1998, The Journal of experimental medicine.

[19]  S. Handt,et al.  Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. , 1996, Immunopharmacology.

[20]  C. Logothetis,et al.  Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma , 1994 .

[21]  R. Coleman.  Evaluation of bone disease in breast cancer , 1994 .

[22]  O. S. Nielsen,et al.  Bone metastases: pathophysiology and management policy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Mull,et al.  Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Giacco,et al.  Osseous metastases secondary to renal cell carcinoma. , 1981, Urology.

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[26]  T. Eisen.  Thalidomide in solid tumors: the London experience. , 2000, Oncology.

[27]  A. Lichtenstein,et al.  In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates , 1998, Leukemia.

[28]  Demichelis,et al.  Evaluation of the , 1992, Physical review. B, Condensed matter.